腺A2A受体激活对心肌梗塞的缓解作用是由于它对CD4+ T淋巴细胞的作用
相关实验视频
Updated: Jul 17, 2026

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
Published on: April 19, 2011
Zequan Yang1, Yuan-Ji Day, Marie-Claire Toufektsian
1Department of Biomedical Engineering, University of Virginia Health System, Box 800759, Charlottesville, VA 22903, USA. zy6b@virginia.edu
氨酸A2A受体 (A2AR) 的激活通过抑制CD4+T细胞来减少心脏病发作损伤. 这项研究揭示了CD4+ T淋巴细胞是肌肉心脏缺血症/再输液损伤的关键贡献者.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 腺氨酸A2A受体 (A2AR) 的激活已经显示出心脏病发作缓解效应,此前与骨髓衍生细胞有关.
- CD4+ T 淋巴细胞,但不是 CD8+ T 细胞,被确定为肌肉心脏缺血/再输损伤的贡献者.
研究的目的:
- 为了研究CD4+ T淋巴细胞在心肌缺血/反损伤中的作用.
- 为了确定A2AR激活的抗心脏病缓解效果是否通过抑制CD4+T细胞积累和激活来介导.
主要方法:
- 利用了腺A2A受体 (A2AR) 淘汰小鼠和骨髓移植.
- 在心肌梗塞的小鼠模型中,在再注血之前,服用A2AR激动剂ATL146e.
- 评估了心脏病发作的大小,T细胞积累和反注射后的中性粒细胞透.
- 雇佣 CD4+ T 淋巴细胞的采用转移到淋巴细胞缺乏的 Rag1 KO 小鼠中.
主要成果:
- A2AR主因子ATL146e显著降低了T细胞积累和心脏病发作的大小.
- 与野生型小鼠相比,缺乏淋巴细胞的Rag1 KO小鼠表现出较小的心脏病发作.
- 在Rag1KO小鼠中,通过CD4+T细胞的移植增加了心脏病发作的大小,这种效应在野生类型的ATL146e中被阻止,但不是A2ARKO CD4+T细胞.
- 中性粒细胞透与淋巴细胞数量和心脏病发作大小相关.
结论:
- A2AR激活的抗心脏病缓解效果主要通过抑制CD4+T细胞的积累和激活在心脏中进行反.
- CD4+ T 淋巴细胞在心肌缺血/流损伤进展中发挥着关键作用.
更多相关视频
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
相关概念视频
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents